On May 17, 2018 the US Food and Drug Administration announced the approval of a new preventive migraine treatment called Aimovig ® (erenumab). This new drug belongs to a class of medications called CGRP inhibitors (you’ll learn about this technical term below) and provides hope to millions of people living with migraine. Migraine patients and their families around the county rejoiced at the news, as historically there is no migraine-specific preventive treatment. But an undertone of the celebration was a grave concern about the ability to access this new migraine treatment option.
You will be hearing acronym that for many of us means nothing. But trust us that this is something you want to know about:
CGRP stands for Calcitonin Gene-Related Peptide. These drugs are thought to work by inhibiting (stopping) these CGRP neurotransmitters in your brain. We aren’t neurologists or doctors, and you likely aren’t either, but what you should know is CGRP plays a large role in what causes migraines to begin. By stopping the transmission of CGRP, many migraine patients can have fewer migraine days. YES!
The short answer is that it should be available within weeks for your doctor to prescribe, and at GHLF we believe that patients should have access to medications that will help them live healthier, happier lives. So, if you and your doctor think this medication is right for you, you should get it. Period. The End. Unfortunately, insurance companies often don’t share that belief— because these drugs upset their profit objectives.
Here is some more information:
People living with migraine, fighting to try to have even the semblance of a “normal” life sure don’t! You deserve to be pain free.